Research Site

Chambéry 73011

1 studies enrolling now · 3 studies all time

What they study most

Carcinoma, Non-Small Cell Lung, IgAN, Immunoglobulin A Nephropathy, Thrombotic Microangiopathy

Studies at this site

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger — Stopped early